Japan's broader Topix climbed 1.8% to 1,486.05, also its highest finish since March 6, with all but one of the 33 sector sub-indexes on the Tokyo exchange trading higher.
Highly cyclical iron and steel, sea transport and insurance were the top three performing sectors on the main bourse.
Panasonic Corp soared 7.0% after the company said on Monday it was seeing strong demand for battery cells from US partner Tesla Inc and they were in talks to expand their joint plant in Nevada, which is now profitable.
Financials were also in demand. Both Mitsubishi UFJ Financial Group (MUFG) and Sumitomo Mitsui Financial Group (SMBC) climbed 4.1% each, while Dai-ichi Life Holdings and Tokio Marine Holdings added 2.8% and 4.5%, respectively.
Japan's top oil and gas exploration company Inpex Corp rose 3.3% as oil prices climbed to a two month-high on Monday following signs that producers were following through on planned output reductions.
Reflecting investor optimism for Japan's economic reopening, the country's top theme park operator Oriental Land Co Ltd gained 5.5%, which has temporarily closed Tokyo Disneyland and DisneySea because of the coronavirus outbreak.
Bucking the overall market, the Nikkei's heavyweight SoftBank Group Corp shed 2.8% after it reported a stunning $18 billion loss at its Vision Fund, pushing the tech conglomerate to a record loss and highlighting the deepening crisis at its portfolio companies.
Elsewhere, Sony Corp and its financial arm Sony Financial Holdings surged 3.3% and 16.9%, respectively, after the Nikkei newspaper reported Sony will turn Sony Financial into a wholly-owned unit through a tender offer worth about 400 billion yen ($3.7 billion).
Data from Moderna Inc's COVID-19 vaccine, the first to be tested in the United States, showed it produced protective antibodies in a small group of healthy volunteers, the company said on Monday.
MSCI's broadest index of Asia-Pacific shares outside Japan last traded up 1.6% in late Asian trade.
Traders said the news of Moderna's success with a potential coronavirus vaccine trial lifted investors' risk appetite globally.